Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy"
- PMID: 34459468
- DOI: 10.14309/ajg.0000000000001495
Response to "Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy"
Comment in
-
Response to Cheng et al.Am J Gastroenterol. 2021 Dec 1;116(12):2474-2475. doi: 10.14309/ajg.0000000000001513. Am J Gastroenterol. 2021. PMID: 34515670 No abstract available.
Comment on
-
Increased ACE2 Levels and Mortality Risk of Patients With COVID-19 on Proton Pump Inhibitor Therapy.Am J Gastroenterol. 2021 Aug 1;116(8):1638-1645. doi: 10.14309/ajg.0000000000001311. Am J Gastroenterol. 2021. PMID: 34047305
References
-
- Liu JJ, Sloan ME, Owings AH, et al. Increased ACE2 levels and mortality risk of patients with COVID-19 on proton pump inhibitor therapy. Am J Gastroenterol, 2021;116(8):1638–45.
-
- Parasa S, Desai M, Thoguluva Chandrasekar V, et al. Prevalence of gastrointestinal symptoms and fecal viral shedding in patients with coronavirus disease 2019: A systematic review and meta-analysis. JAMA Netw Open 2020;3(6):e2011335.
-
- Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 death using OpenSAFELY. Nature 2020;584:430–6.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
